Moderna mRNA-1273 Vaccination produced serum neutralizing antibodies detected in all the participants at day 119
Vaccine “has the potential to provide durable humoral immunity” against virus, NIAID authors argue Antibody responses to Moderna’s COVID-19 vaccine candidate, mRNA-1273, remained strong for almost 4 months following vaccination, data from a phase I trial indicated. Serum neutralizing antibodies were detected in 34 healthy adult volunteers at day 119 following the first dose, and